“It is my opinion that revolutionary changes often happen faster than ‘organic’ changes. They may seem improbable or even impossible, but once the first shot is fired, change occurs rapidly… Unthinkable at first, and then unfathomable as to what took so long.”
—Stuart Firestein, “Failure”
- PhD, Chemistry, Yale University
- BS, Chemistry and Applied Math, Fairfield University
- Current Affiliation
- Other Links
- Google Scholar
Mark Murcko was an early leader in structure-based drug design and has directly contributed to nine marketed drugs spanning HIV, cystic fibrosis, and glaucoma. He is a Founder, Board member, and was the interim CSO at Relay Therapeutics. In addition, Mark is a senior lecturer in the Department of Biological Engineering at MIT, and has served on numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations. Mark was chief technology officer and chair of the SAB of Vertex Pharmaceuticals and was responsible for the identification, validation and implementation of disruptive technologies across R&D. Mark is a co-inventor of the HCV protease inhibitor Incivek (telaprevir), as well as Agenerase (amprenavir) and Lexiva (fosamprenavir), Vertex’s two marketed drugs for the treatment of HIV. In addition, he guided the early efforts of Vertex’s cystic fibrosis program that later produced four marketed drugs.
Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover multiple clinical candidates, including Trusopt (Dorzolamide), a carbonic anhydrase inhibitor for the treatment of glaucoma. This was the first medicine in history to come from a structure-based drug design program. He is a member of the Board of Trustees of the GRC and the Board of Advisors of the Boston Museum of Science. He is a co-inventor on more than 50 issued and pending patents and has co-authored more than 85 scientific articles. Mark holds a Ph.D. in organic chemistry from Yale University.